linjc16/ctgov huggingface dataset:
UVA1 Phototherapy in Acral Vitiligo

Study Overview
=================
Brief Summary
-----------------
evaluate the effect of UVA1 phototherapy in the treatment of acral vitiligo.

Official Title
-----------------
The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo

Conditions
-----------------
Acral Vitiligo

Intervention / Treatment
-----------------
* Other: phototherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acral vitiligo. Patients more than 12 years old. Exclusion Criteria: Patients less than 12 years old. Patients with any other skin diseases or autoimmune diseases. Patients taking medical treatment or phototherapy for vitiligo.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: UVA1 phototherapy<br>UVA1 phototherapy in acral vitiligo | Other: phototherapy<br>* phototherapy either UVA1 or topical PUVA on acral vitiligo<br>|
| Active Comparator: Topical PUVA<br>Topical PUVA in acral vitiligo | Other: phototherapy<br>* phototherapy either UVA1 or topical PUVA on acral vitiligo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effect of medium dose UVA1 phototherapy in treatment of acral vitiligo | effect of medium dose UVA1 phototherapy in treatment of acral vitiligo using point counting and vitiligo area severity index (VASI) score | 1 year |
Neurological Outcome in Patients of Traumatic Subarachnoid Haemorrhage

Study Overview
=================
Brief Summary
-----------------
Traumatic brain injury is common cause of morbidity and mortality worldwide. Incidence and pattern of traumatic brain injury varies in developed and developing countries. Subarachnoid haemorrhage refers to blood in subarachnoid space that lies between arachnoid and piameninges, covering brain. It is often associated with concurrent intracranial injury component. Individuals at higher risk for tSAH are those who are at higher risk for blunt head trauma. This includes adolescents, low-income individuals, men, and individuals with a history of substance abuse. The investigators present study aims to investigate prognostic factors associated with the neurological outcome among patients of post traumatic SAH.

Official Title
-----------------
Incidence and Outcomes of Traumatic Subarachnoid Haemorrhage Patients: A Cross Sectional Study

Conditions
-----------------
Traumatic Subarachnoid Haemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients of traumatic subarachnoid haemorrhage Exclusion Criteria: Metabolic disorder Altered coagulation profile Cardiac disease Co- morbid illness
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| traumatic subarachnoid haemorrhage<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of consciousness measured by Glasgow coma scale |  | Change from baseline to one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| appearance of subarachnoid hemorrhage on CT measured by Fisher Grading |  | Change from baseline to one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
traumatic Subarachnoid Haemorrhage, Head Trauma, Computed Tomography
The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.

Study Overview
=================
Brief Summary
-----------------
Nutritional status in patients with neuroendocrine tumours (NETs), especially of gastroenteropancreatic origin, can be deeply affected by excessive production of gastrointestinal hormones, peptides, and amines, which can lead to malabsorption, diarrhoea, steatorrhea, and altered gastrointestinal motility. Besides, the surgical and/or medical management of NETs can lead to alteration of gastrointestinal secretory, motor, and absorptive functions, with both dietary and nutritional consequences. Indeed, disease-related malnutrition is a frequently encountered yet both underrecognized and understudied clinical phenomenon in patients with NETs, with substantial prognostic and socioeconomic consequences. Most of these conditions can be alleviated by a tailored nutritional approach, also with the aim of improving the efficacy of cancer treatments. In this setting, skilled nutritionists can play a fundamental role in the multidisciplinary health care team in NETs management and their presence should be recommended.

Official Title
-----------------
Association Between Mediterranean Diet and Neuroendocrine Tumours.

Conditions
-----------------
Mediterranean Diet, Neuroendocrine Tumours (NETs)

Intervention / Treatment
-----------------
* Dietary Supplement: Mediterranean diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with neuroendocrine tumours (NETs) Exclusion Criteria: age>65 years < BMI 19 kg/m2 vegetarians

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: Mediterranean diet|We aim to determine the effects of the traditional Mediterranean Diet on neuroendocrine tumours|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence to Mediterranean Diet by Predimed Questionnaire | Validated 14-item tool of adherence to the Mediterranean diet, with three categories of adherence (≤5, low adherence, 6-9, average adherence and ≥10 points, high adherence) | December 2017 to June 2018 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body composition | BIA was performed using a BIA phase-sensitive system by experienced observers (an 800-µA current at a frequency single-frequency of 50 kHz BIA 101 RJL, Akern Bioresearch, Florence, Italy) | December 2017 to June 2018 |
Online Treatment of Trichotillomania

Study Overview
=================
Brief Summary
-----------------
Online study for patients with trichotillomania. 4 main hypothesis. Alexithymia and Trichotillomania correlated and regression analyses find association between them we will be able to find patient who have never been treated before. Those will suffer to the same amount as previously treated patients Decoupling will be more helpful than progressive muscle relaxation different constructs of emotion regulation will show different trait and state characteristics in patients with trichotillomania

Detailed Description
-----------------
Randomized controlled trial with about 100 participants.

Official Title
-----------------
Decoupling as Internet Based Intervention: an Randomized Controlled Study to Treat Trichotillomania

Conditions
-----------------
Trichotillomania, Alexithymia, Quality of Life

Intervention / Treatment
-----------------
* Behavioral: Decoupling
* Behavioral: Progressive relaxation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suffering from trichotillomania 18 to 65 years old Exclusion Criteria: current drug or alcohol addiction current psychosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Decoupling<br>specific technic to reduce hair pulling | Behavioral: Decoupling<br> <br> |
| Active Comparator: progressive muscle relaxation<br>Progressive relaxation relaxation technic | Behavioral: Progressive relaxation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of trichotillomania |  | 7 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| alexithymia |  | 7 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
trichotillomania, online therapy
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
A new type of treatment called stereotactic radiotherapy has recently been developed in hopes of improving the success of the treatment and improving the convenience to patients, while reducing the side effects. This study is developing stereotactic radiotherapy as a state-of-the-art treatment for lung cancer patients.

Detailed Description
-----------------
OBJECTIVES: Primary Objectives To determine the efficacy of hypofractionated, image guided radiotherapy in treating patients with lung tumours, with the primary outcome being local control at one year. To determine the toxicity of high dose, small field,hypofractionated radiotherapy to the lung, based on the RTOG and CTCAE scales.

Official Title
-----------------
Multicentre, Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Early Stage Non-Small Cell Lung Cancer (NSCLC)

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Radiation: Stereotactic Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: T1-T3N0 non-small cell lung cancer (maximum dimensions of 5cm, T3 by chestwall involvement only) Medically inoperable due to co-morbid conditions or patient preference for radiation adequate pulmonary function to withstand radical treatment (ie. FEV1 greater than 40% of predicted), as assessed by consulting radiation oncologist age greater than or equal to 18, and Karnofsky performance status greater than of equal to 70 Exclusion Criteria: Presence of mediastinal metastases or distant metastases Life expectancy less than 1 year due to other co-morbid conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Stereotactic Radiotherapy|Stereotactic Radiotherapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Local Control |  | One Year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxicity |  | One Year | 
| Quality of Life |  | One Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fractionated stereotactic radiotherapy, Medically inoperable, Image-guided radiotherapy
Femoral Artery Crossover Rates in 1000 Consecutive Radial Cath Labs Procedures.

Study Overview
=================
Brief Summary
-----------------
Comparison of Crossover rates of Radial Cardiac Catheterizations and/or PCIs into femoral vs published literature

Detailed Description
-----------------
A retrospective review of 1000 consecutive Radial or Ulnar Cardiac Catheterizations and/or Percutaneous Coronary Interventions performed in our Institute by one single operator could provide us with the cross over rates to femoral interventions. In this manner these rates could be compared to the published rates of other institutions benchmarking our techniques with the outcomes for such interventions.

Official Title
-----------------
Femoral Artery Crossover Rates of 1000 Consecutive Radial (or Ulnar) Artery Procedures in the Cardiac Cath Lab for Diagnostic Cardiac Catheterizations and/or Percutaneous Coronary Interventions

Conditions
-----------------
Retrospective Review

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients coming to the emergency room requiring Diagnostic Cardiac Catheterizations and/or Percutaneous Coronary Interventions Exclusion Criteria: Cardiac Tamponade Cardiogenic Shock

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Crossover rate from Radial to Femoral access | How often do you start a Cath on the Radial Artery and for any reason, have to switch to Femoral Artery. | 1 year |
Regimens Comparison for Breast Cancers of Positive Lymph Nodes

Study Overview
=================
Brief Summary
-----------------
To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes

Detailed Description
-----------------
EC-T regimen: epirubicin 90mg/m2 day1, CTX 600mg/m2, day 1, 21 days per cycle *4cycle. followed by paclitaxel 175mg/m2,d1,21days per cycle, 4 cycle. ET regimen: epirubicin 75mg/m2 day1,paclitaxel 175mg/m2,d2,21days per cycle, 6 cycle

Official Title
-----------------
Phase 3 Study of Regimens Comparison for Breast Cancers of Positive Lymph Nodes

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Epirubicin, CTX, Paclitaxel
* Drug: Epirubicin, Paclitaxel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with breast cancer after breast cancer surgery with positive lymph nodes age 18-70 years old Exclusion Criteria: with other malignance disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group A: EC-T regimen<br> | Drug: Epirubicin, CTX, Paclitaxel<br>* Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.<br>|
| Experimental: Group B: ET regimen<br> | Drug: Epirubicin, Paclitaxel<br>* Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS |  | 5 years after all the recuiment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS |  | 5 years after all the adjuvent treatments | 
| Safety | Assessing for Hematology and Non-hematology toxicities, including all SAEs. | 5 years after all the recruiment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
positive lymph node
The Effect of Light Emitting Diode Phototherapy on the Rate of Orthodontic Tooth Movement - A Clinical Study

Study Overview
=================
Brief Summary
-----------------
LED Phototherapy will increase the velocity of Orthodontic tooth movement.

Official Title
-----------------
The Effect of Light Emitting Diode Phototherapy on the Rate of Orthodontic Tooth Movement - A Clinical Study

Conditions
-----------------
The Rate or Orthodontic Tooth Movement

Intervention / Treatment
-----------------
* Device: LED Phototherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bilaterally symmetric extraction of premolar teeth with residual extraction spaces large enough to ensure space closure is not complete prior to the subsequent orthodontic appointment no medicines or systemic illness full banding/bonding of teeth Exclusion Criteria: pregnant non-extraction treatment systemic illness prior orthodontic treatment

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: LED Phototherapy<br>LED phototherapy will be delivered transdermally via an extra-oral device and in a split mouth manner (half of the dental arch). | Device: LED Phototherapy<br> <br> * Other names: Device manufactured by Biolux Research Ltd;|
| No Intervention: Control: conventional orthodontic tooth movement<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extraction space size | T0=the start of active extraction space closure T1=3-7 weeks after T0 T2=4-7 weeks after T1 | T0, T1, T2 |
Subjects Through the Application of the Mindera Kit Part 2

Study Overview
=================
Brief Summary
-----------------
A 16 week study to examine if baseline or on-therapy transcriptomics can be used to help predict selection of medications and provide new therapeutic targets for drug development in psoriasis subjects.

Official Title
-----------------
An Exploratory, Multicenter, Observational Study to Examine RNA Biomarkers of Psoriasis Subjects Through the Application of the Mindera Kit Part 2 (STAMP-2).

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Other: Mindera Kit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Subject must have the ability to understand and sign written informed consent. Subject must be an adult male or female adult who is ≥ 18 years of age at the time of screening. Subject must be diagnosed with psoriasis by either a dermatologist or a rheumatologist, with the affected area of ≥ 2 centimeters in diameter. Subjects must be treated with anti-TNF-α (or biosimilar) therapy once enrolled in the study.A two-week period is required to washout of the previous biologic when switching therapies. Exclusion Criteria Subject is unable or unwilling to give written informed consent and/or to comply with study procedures. Subject has had usage of topical psoriasis treatments on study lesion within 2 weeks prior to baseline studyvisit and unwilling to washout. Subjects currently treated with Hydroxychloroquine (Plaquenil), unless otherwise approved by Sponsor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observation of on therapy transcriptomics to potentially aid in new therapeutic targets | To examine if baseline or on-therapy transcriptomics can be used to help predict selection of medications and provide new therapeutic targets for drug development in psoriasis subjects by collecting RNA and examining changes in PASI scores at the Week 4, 12, and 16 timepoints. | 16 weeks |
Comparison of Monitors of Fluid Therapy

Study Overview
=================
Brief Summary
-----------------
The investigators want to correlate different methods to guide fluid therapy. The investigators know that guidance by esophagus doppler technique has improved outcome and want to correlate other already used techniques to esophagus doppler.

Detailed Description
-----------------
Fluid therapy before and under surgery can be guided by measurement of the hearts ability to eject blood (cardiac output). By doing this it has been shown that the occurrence of nausea,vomiting and complications generally can be reduced. The function of the heart has been measured with a probe in the esophagus in in earlier studies. We want to correlate these results with other techniques by which fluid therapy also is guided in daily practice. These are: SVO2, modelflow (finapres)and NIRS. These methods are noninvasive except SVO2 measurement which requires a central venous catheter (CVK). Therefore we have chosen a population in which CVK is standard in our institution. We thereby don´t apply any further risks than daily practice and the project is considered as a quality assessment of used standards.

Official Title
-----------------
Comparison of Monitors of Fluid Therapy

Conditions
-----------------
Hypovolemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Elective urological surgery in which a central venous catheter is routinely administered Informed consent Exclusion Criteria: Age 70 years or older No informed consent Pathology in the esophagus that contraindicates use off gastric tube and esophagus doppler ASA III or above

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fluid therapy, Monitoring